Treatment of an inherited disorder of cholesterol metabolism by pathogenesis-based therapy
Not Applicable
Completed
- Conditions
- an inherited disorder of cholesterol metabolism
- Registration Number
- JPRN-UMIN000024307
- Lead Sponsor
- Department of Pediatrics, Tohoku University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
Not provided
Exclusion Criteria
Past histroy of allergic reaction for atorvastatin Severe hepatic disease/disorder (AST or ALT > normal limits*1.25) During administration of Telaprevir Women who are or may be pregnant Participants in other clinical trials or researchs at the registration Patients who are judged inappropriate for the trial by lead principal investigator or other participating doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of skin condition after 24 weeks of treatment
- Secondary Outcome Measures
Name Time Method Evaluation of intermediate of cholesterol in the patients' skin Skin biopsy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pathogenesis-based cholesterol metabolism disorder therapies?
How effective is pathogenesis-based therapy compared to standard treatments for inherited cholesterol disorders?
What biomarkers are used to select patients for pathogenesis-based cholesterol metabolism therapy?
What adverse events are associated with pathogenesis-based cholesterol metabolism treatments?
Are there combination therapies or alternative drugs for inherited cholesterol metabolism disorders?